{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3593, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de075-cc4c-7798-ab9a-10371ba4eaba", "docSlug": "b837a96ddd48514a32becf4a4bebecac", "documentTitle": "Sonos | Results Presentation Deck | 33 slides", "authorId": "sonos", "authorName": "Sonos", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Uses a nested circle diagram to show market segmentation and penetration.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cc4c-7798-ab9a-10371ba4eaba/26", "deckHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba", "deckAnchorHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cc4c-7798-ab9a-10371ba4eaba", "docSlug": "b837a96ddd48514a32becf4a4bebecac", "documentTitle": "Sonos | Results Presentation Deck | 33 slides", "authorId": "sonos", "authorName": "Sonos", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "before_after", "function": "present_solution", "notes": "Uses a chevron-style arrow to indicate progression from current state to future state.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cc4c-7798-ab9a-10371ba4eaba/27", "deckHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba", "deckAnchorHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cc4c-7798-ab9a-10371ba4eaba", "docSlug": "b837a96ddd48514a32becf4a4bebecac", "documentTitle": "Sonos | Results Presentation Deck | 33 slides", "authorId": "sonos", "authorName": "Sonos", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide tracks the shift in revenue mix towards higher-margin channels.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cc4c-7798-ab9a-10371ba4eaba/28", "deckHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba", "deckAnchorHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cc4c-7798-ab9a-10371ba4eaba", "docSlug": "b837a96ddd48514a32becf4a4bebecac", "documentTitle": "Sonos | Results Presentation Deck | 33 slides", "authorId": "sonos", "authorName": "Sonos", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Includes non-GAAP financial measures and constant currency growth rates.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cc4c-7798-ab9a-10371ba4eaba/29", "deckHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba", "deckAnchorHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cc4c-7798-ab9a-10371ba4eaba", "docSlug": "b837a96ddd48514a32becf4a4bebecac", "documentTitle": "Sonos | Results Presentation Deck | 33 slides", "authorId": "sonos", "authorName": "Sonos", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cc4c-7798-ab9a-10371ba4eaba/30", "deckHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba", "deckAnchorHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cc4c-7798-ab9a-10371ba4eaba", "docSlug": "b837a96ddd48514a32becf4a4bebecac", "documentTitle": "Sonos | Results Presentation Deck | 33 slides", "authorId": "sonos", "authorName": "Sonos", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "appendix_data", "function": "analyze_data", "notes": "Financial data in thousands, unaudited. Includes detailed footnotes explaining legal/transaction costs and restructuring/abandonment costs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cc4c-7798-ab9a-10371ba4eaba/31", "deckHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba", "deckAnchorHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cc4c-7798-ab9a-10371ba4eaba", "docSlug": "b837a96ddd48514a32becf4a4bebecac", "documentTitle": "Sonos | Results Presentation Deck | 33 slides", "authorId": "sonos", "authorName": "Sonos", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes footnotes explaining legal/transaction costs and the 2023 restructuring plan.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cc4c-7798-ab9a-10371ba4eaba/32", "deckHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba", "deckAnchorHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cc4c-7798-ab9a-10371ba4eaba", "docSlug": "b837a96ddd48514a32becf4a4bebecac", "documentTitle": "Sonos | Results Presentation Deck | 33 slides", "authorId": "sonos", "authorName": "Sonos", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "appendix_data", "function": "analyze_data", "notes": "Note: $ in thousands, unaudited.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cc4c-7798-ab9a-10371ba4eaba/33", "deckHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba", "deckAnchorHref": "/decks/019de075-cc4c-7798-ab9a-10371ba4eaba#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/Qf4pw8R8GXDTSmAYjVR-4L5W1uHxkVl_c3dy7pEfYSQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xNmIyZDc1OTJmNDYzNGFjN2NkNzE3YTk5NjkzNGYwNy9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/1", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "0a4a0850-3127-4a02-80c9-3036a1e29255", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with a cover page, disclaimer, and agenda, grabbing the audience's attention", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/vQV4xV3mZnOhjX71kZWEOACK7JzSv9lin7-M9-tsC34/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xNmIyZDc1OTJmNDYzNGFjN2NkNzE3YTk5NjkzNGYwNy9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/Bx13U-HcfpHWAHPEBCF8dY0-mYZmwy6hzJERCtz3arc/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xNmIyZDc1OTJmNDYzNGFjN2NkNzE3YTk5NjkzNGYwNy9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/0mxBeG8QNNrM6GAJu4zz7KEOWsWD5MiVD6Ecdv-EZEI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xNmIyZDc1OTJmNDYzNGFjN2NkNzE3YTk5NjkzNGYwNy9wMDAxLnBuZw" }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/2", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "0a4a0850-3127-4a02-80c9-3036a1e29255", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with a cover page, disclaimer, and agenda, grabbing the audience's attention", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "agenda", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/3", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "0a4a0850-3127-4a02-80c9-3036a1e29255", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with a cover page, disclaimer, and agenda, grabbing the audience's attention", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "key_messages", "function": "summarize", "notes": "The slide uses a three-column layout to categorize strategic priorities.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/4", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "0a4a0850-3127-4a02-80c9-3036a1e29255", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with a cover page, disclaimer, and agenda, grabbing the audience's attention", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/5", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "0a4a0850-3127-4a02-80c9-3036a1e29255", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with a cover page, disclaimer, and agenda, grabbing the audience's attention", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "cover", "function": "front_matter", "notes": "Slide serves as a product introduction/cover slide for a corporate presentation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/6", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 6, "beatId": "1fbb30a4-8963-45ab-9835-718fe3d33065", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "The document highlights the addressable population for YUPELRI and the unmet need for MSA patients", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "kpi_overview", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/7", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 6, "beatId": "1fbb30a4-8963-45ab-9835-718fe3d33065", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "The document highlights the addressable population for YUPELRI and the unmet need for MSA patients", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide shows two line charts tracking market share growth in different care settings.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/8", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 6, "beatId": "1fbb30a4-8963-45ab-9835-718fe3d33065", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "The document highlights the addressable population for YUPELRI and the unmet need for MSA patients", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide highlights consistent growth in both metrics, with Q/Q growth percentages annotated above each bar.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/9", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 6, "beatId": "1fbb30a4-8963-45ab-9835-718fe3d33065", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "The document highlights the addressable population for YUPELRI and the unmet need for MSA patients", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Uses a Venn diagram to illustrate the patient segments (Dexterity Challenges, Cognitive Impairment, Suboptimal PIFR) that define the addressable population.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/10", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-10", "loopMatches": [ { "to": 17, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f", "evidence": "The document highlights the significant unmet need for MSA patients", "position": 1, "objective": "Emphasizing the cost of inaction for MSA patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 6, "beatId": "1fbb30a4-8963-45ab-9835-718fe3d33065", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "The document highlights the addressable population for YUPELRI and the unmet need for MSA patients", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/11", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-11", "loopMatches": [ { "to": 17, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f", "evidence": "The document highlights the significant unmet need for MSA patients", "position": 1, "objective": "Emphasizing the cost of inaction for MSA patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 18, "from": 11, "beatId": "ae4646ce-73d8-418d-9390-888b787632a7", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide outlines a clinical trial methodology using a timeline-based study design.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/12", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-12", "loopMatches": [ { "to": 17, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f", "evidence": "The document highlights the significant unmet need for MSA patients", "position": 1, "objective": "Emphasizing the cost of inaction for MSA patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 18, "from": 11, "beatId": "ae4646ce-73d8-418d-9390-888b787632a7", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "before_after", "function": "analyze_data", "notes": "The slide illustrates how findings from one study (PIFR-1) informed the design of a subsequent study (PIFR-2) by narrowing the patient population to GOLD 3/4, resulting in statistically significant improvement.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/13", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-13", "loopMatches": [ { "to": 17, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f", "evidence": "The document highlights the significant unmet need for MSA patients", "position": 1, "objective": "Emphasizing the cost of inaction for MSA patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 18, "from": 11, "beatId": "ae4646ce-73d8-418d-9390-888b787632a7", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/14", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-14", "loopMatches": [ { "to": 17, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f", "evidence": "The document highlights the significant unmet need for MSA patients", "position": 1, "objective": "Emphasizing the cost of inaction for MSA patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 18, "from": 11, "beatId": "ae4646ce-73d8-418d-9390-888b787632a7", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "other", "function": "present_framework", "notes": "The slide outlines a clinical trial design using a randomized withdrawal methodology.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/15", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-15", "loopMatches": [ { "to": 17, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f", "evidence": "The document highlights the significant unmet need for MSA patients", "position": 1, "objective": "Emphasizing the cost of inaction for MSA patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 18, "from": 11, "beatId": "ae4646ce-73d8-418d-9390-888b787632a7", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a combination of a market sizing summary at the top and a competitive landscape table at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/16", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-16", "loopMatches": [ { "to": 17, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f", "evidence": "The document highlights the significant unmet need for MSA patients", "position": 1, "objective": "Emphasizing the cost of inaction for MSA patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 18, "from": 11, "beatId": "ae4646ce-73d8-418d-9390-888b787632a7", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a classic 'problem vs. solution' or 'market gap vs. strategic imperative' structure.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/17", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-17", "loopMatches": [ { "to": 17, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f", "evidence": "The document highlights the significant unmet need for MSA patients", "position": 1, "objective": "Emphasizing the cost of inaction for MSA patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 18, "from": 11, "beatId": "ae4646ce-73d8-418d-9390-888b787632a7", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/18", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 11, "beatId": "ae4646ce-73d8-418d-9390-888b787632a7", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes GAAP and non-GAAP financial measures.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/19", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 19, "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The document outlines the company's financial update and expected milestones", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide provides a standard financial reconciliation table.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/20", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 19, "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The document outlines the company's financial update and expected milestones", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide includes specific footnotes regarding non-GAAP adjustments and share buyback activity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/21", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-21", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 19, "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The document outlines the company's financial update and expected milestones", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart shows a significant reduction in operating expenses from 2020 to 2023.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/22", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-22", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 19, "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The document outlines the company's financial update and expected milestones", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "kpi_overview", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/23", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 19, "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The document outlines the company's financial update and expected milestones", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "valuation_table", "function": "analyze_data", "notes": "The table displays projected royalties, net sales, and milestone payments from 2023 to 2026.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/24", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 19, "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The document outlines the company's financial update and expected milestones", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "thesis_headline", "function": "present_solution", "notes": "Uses a curved arrow diagram to represent a progression or portfolio of value drivers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/25", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-25", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 19, "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The document outlines the company's financial update and expected milestones", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "closing_ask", "function": "state_next_steps", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/26", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "disclaimer", "function": "other", "notes": "Standard pharmaceutical product disclosure slide.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/27", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "key_messages", "function": "establish_context", "notes": "Includes a footnote referencing market research methodology.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/28", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/29", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes definitions for COPD, nOH, and PTE in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/30", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "revenue_buildup", "function": "present_framework", "notes": "The slide uses a mathematical equation format to explain the revenue recognition process.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/31", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "comparison_table", "function": "analyze_data", "notes": "The slide uses a split-panel layout to compare two distinct deal structures.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/32", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "other", "function": "other", "notes": "This slide serves as a reference or bibliography page for a conference presentation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/33", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "before_after", "function": "present_solution", "notes": "Uses a before-after framing to justify a strategic pivot in clinical trial focus.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/34", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-34", "loopMatches": [ { "to": 35, "from": 34, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "2342bbb8-7106-4ccd-9663-bc88e95faeaa", "evidence": "The document shows a clear before-and-after comparison of the program's focus", "position": 0, "objective": "Highlighting the evolution of the program", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.6, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cd17-7685-9273-fb1c731af40f", "docSlug": "16b2d7592f4634ac7cd717a996934f07", "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/35", "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f", "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-35", "loopMatches": [ { "to": 35, "from": 34, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "2342bbb8-7106-4ccd-9663-bc88e95faeaa", "evidence": "The document shows a clear before-and-after comparison of the program's focus", "position": 0, "objective": "Highlighting the evolution of the program", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.6, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/6MEFyRgytzFEmne2Hu8Nbwlm2MVx_aiAIMHsqB8xco0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xMTFiYzg5MTI4Njc1MGRiNDJjNmNiNzEwZDJhNjNjYi9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/1", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "ab81eb4f-8a97-43d7-95cf-4a2f54a70c57", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with key messages and an overview of UBS's strategy", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/WU56s9zUQvRxXvhz9AY9FqpMQTTUAwqSFXgLFZq9P-U/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xMTFiYzg5MTI4Njc1MGRiNDJjNmNiNzEwZDJhNjNjYi9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/wZsyAGioh14uTZvOR-z38yJ4ednE4YCqVqwqb1w5KxE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xMTFiYzg5MTI4Njc1MGRiNDJjNmNiNzEwZDJhNjNjYi9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/8VtLEiY_yR3SDzSlmPPmBUlwHIpXQgTl67Q2L6s0MS0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xMTFiYzg5MTI4Njc1MGRiNDJjNmNiNzEwZDJhNjNjYi9wMDAxLnBuZw" }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 2, "slideType": "disclaimer", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/2", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "ab81eb4f-8a97-43d7-95cf-4a2f54a70c57", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with key messages and an overview of UBS's strategy", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 3, "slideType": "table_of_contents", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/3", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "ab81eb4f-8a97-43d7-95cf-4a2f54a70c57", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with key messages and an overview of UBS's strategy", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 4, "slideType": "key_messages", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/4", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "ab81eb4f-8a97-43d7-95cf-4a2f54a70c57", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Attention", "beatSlug": "monroes-sequence-attention", "evidence": "The document starts with key messages and an overview of UBS's strategy", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 5, "slideType": "key_messages", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/5", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-5", "loopMatches": [ { "to": 10, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "323ff73d-01ae-446c-91cf-014007f48c03", "evidence": "UBS highlights the need for integration and cost reductions", "position": 0, "objective": "What are the consequences of not integrating Credit Suisse?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 5, "beatId": "f0c5d50e-7a92-4a55-a821-64d3a39d0e95", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "UBS highlights the need for integration and cost reductions", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 6, "slideType": "key_messages", "function": "summarize", "notes": "The slide uses a four-column layout to delineate business units, each with a strategic objective and supporting bullet points.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/6", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-6", "loopMatches": [ { "to": 10, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "323ff73d-01ae-446c-91cf-014007f48c03", "evidence": "UBS highlights the need for integration and cost reductions", "position": 0, "objective": "What are the consequences of not integrating Credit Suisse?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 5, "beatId": "f0c5d50e-7a92-4a55-a821-64d3a39d0e95", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "UBS highlights the need for integration and cost reductions", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 7, "slideType": "propose_solution", "function": "propose_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/7", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-7", "loopMatches": [ { "to": 10, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "323ff73d-01ae-446c-91cf-014007f48c03", "evidence": "UBS highlights the need for integration and cost reductions", "position": 0, "objective": "What are the consequences of not integrating Credit Suisse?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 5, "beatId": "f0c5d50e-7a92-4a55-a821-64d3a39d0e95", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "UBS highlights the need for integration and cost reductions", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 8, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses grouped bar charts to compare UBS and Credit Suisse performance metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/8", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-8", "loopMatches": [ { "to": 10, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "323ff73d-01ae-446c-91cf-014007f48c03", "evidence": "UBS highlights the need for integration and cost reductions", "position": 0, "objective": "What are the consequences of not integrating Credit Suisse?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 5, "beatId": "f0c5d50e-7a92-4a55-a821-64d3a39d0e95", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "UBS highlights the need for integration and cost reductions", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 9, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide details the composition of the Non-core and Legacy (NCL) perimeter, highlighting the wind-down of Credit Suisse assets.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/9", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-9", "loopMatches": [ { "to": 10, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "323ff73d-01ae-446c-91cf-014007f48c03", "evidence": "UBS highlights the need for integration and cost reductions", "position": 0, "objective": "What are the consequences of not integrating Credit Suisse?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 5, "beatId": "f0c5d50e-7a92-4a55-a821-64d3a39d0e95", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "UBS highlights the need for integration and cost reductions", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 10, "slideType": "propose_solution", "function": "propose_solution", "notes": "The chart shows a projected decline in RWA from 55bn in 2Q23 to 28bn in YE26.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/10", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-10", "loopMatches": [ { "to": 10, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "323ff73d-01ae-446c-91cf-014007f48c03", "evidence": "UBS highlights the need for integration and cost reductions", "position": 0, "objective": "What are the consequences of not integrating Credit Suisse?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 5, "beatId": "f0c5d50e-7a92-4a55-a821-64d3a39d0e95", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Need", "beatSlug": "monroes-sequence-need", "evidence": "UBS highlights the need for integration and cost reductions", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 11, "slideType": "propose_solution", "function": "present_solution", "notes": "The slide uses a logic flow from strategic levers (left) to financial targets (right).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/11", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-11", "loopMatches": [ { "to": 21, "from": 11, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "e850b26c-87ce-40d5-9049-8d7df41fb032", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 1, "objective": "Can UBS achieve its financial goals through integration?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 21, "from": 11, "beatId": "0953f5e5-8c1b-4cbb-970a-e4e1cd6c2d48", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 12, "slideType": "sop_buildup", "function": "present_solution", "notes": "The chart shows a bridge from current state to 2026 exit rate via four strategic levers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/12", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-12", "loopMatches": [ { "to": 21, "from": 11, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "e850b26c-87ce-40d5-9049-8d7df41fb032", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 1, "objective": "Can UBS achieve its financial goals through integration?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 21, "from": 11, "beatId": "0953f5e5-8c1b-4cbb-970a-e4e1cd6c2d48", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 13, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/13", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-13", "loopMatches": [ { "to": 21, "from": 11, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "e850b26c-87ce-40d5-9049-8d7df41fb032", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 1, "objective": "Can UBS achieve its financial goals through integration?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 21, "from": 11, "beatId": "0953f5e5-8c1b-4cbb-970a-e4e1cd6c2d48", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 14, "slideType": "revenue_buildup", "function": "analyze_data", "notes": "The chart illustrates the impact of the Credit Suisse acquisition on 2Q23 results.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/14", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-14", "loopMatches": [ { "to": 21, "from": 11, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "e850b26c-87ce-40d5-9049-8d7df41fb032", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 1, "objective": "Can UBS achieve its financial goals through integration?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 21, "from": 11, "beatId": "0953f5e5-8c1b-4cbb-970a-e4e1cd6c2d48", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 15, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "The slide uses two waterfall charts to explain the financial impact of the Credit Suisse acquisition.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/15", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-15", "loopMatches": [ { "to": 21, "from": 11, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "e850b26c-87ce-40d5-9049-8d7df41fb032", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 1, "objective": "Can UBS achieve its financial goals through integration?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 21, "from": 11, "beatId": "0953f5e5-8c1b-4cbb-970a-e4e1cd6c2d48", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 16, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses stacked bar charts to illustrate capital structure in absolute terms (bn) and relative terms (%), comparing current status to regulatory requirements.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/16", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-16", "loopMatches": [ { "to": 21, "from": 11, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "e850b26c-87ce-40d5-9049-8d7df41fb032", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 1, "objective": "Can UBS achieve its financial goals through integration?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 21, "from": 11, "beatId": "0953f5e5-8c1b-4cbb-970a-e4e1cd6c2d48", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-cdb7-7044-8ab7-a6598b346b12", "docSlug": "111bc891286750db42c6cb710d2a63cb", "documentTitle": "UBS | Fixed Income Presentation Deck | 44 slides", "authorId": "ubs", "authorName": "UBS", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 17, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart shows the reduction of drawn SNB facilities from 120bn to 0 between March and August 2023.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-cdb7-7044-8ab7-a6598b346b12/17", "deckHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12", "deckAnchorHref": "/decks/019de075-cdb7-7044-8ab7-a6598b346b12#slide-17", "loopMatches": [ { "to": 21, "from": 11, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "e850b26c-87ce-40d5-9049-8d7df41fb032", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 1, "objective": "Can UBS achieve its financial goals through integration?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 21, "from": 11, "beatId": "0953f5e5-8c1b-4cbb-970a-e4e1cd6c2d48", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "UBS presents its progress on cost reductions and financial performance", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }